Augmenting Bioinformatics Research with Biomedical Ontologies

Total Page:16

File Type:pdf, Size:1020Kb

Augmenting Bioinformatics Research with Biomedical Ontologies Waclaw Kusnierczyk Augmenting Bioinformatics Research with Biomedical Ontologies PhD thesis 2008 Department of Computer and Information Science Faculty of Information Technology, Mathematics and Electrical Engineering Norwegian University of Science and Technology i Abstract The main objective of the reported study was to investigate how biome- dical ontologies, logically structured representations of various aspects of the biomedical reality, can help researchers in analyzing experimental data. High-throughput technologies, such as platforms for microarray gene ex- pression experiments (MAGE), yield increasingly large amounts of ‘massive’ data; successful analyses of the data require expertise in the application do- main, and to support researchers with automated methods explicit domain knowledge representations are often essential. Two attempts to construct such tools are reported here: one successful — eGOn, a web-based tool for mapping the results of microarray gene expression experiments onto the structure of the Gene Ontology; and one unsuccessful — a framework for knowledge- and case-based enhancement of biological association network- building tools. Ontologies — structured, computer-understandable accounts of expert kno- wledge — are a relatively new invention. Until only recently, biomedical ontologies were developed with little care for formal semantics, syntactic and semantic compatibility with each other, and the ontological (in a philo- sophical sense) commitments made. However, for successful integration of resources that use different ontologies to describe their content and services, integration on the ontological level is needed. While one way to achieve this is to apply some of the much-researched techniques of ontology alignment and merging, another approach is to organize the ontology creation move- ment around a common basis — a unique top-level ontology and a set of design principles. Some of such integrative efforts made by the community of Open Biomedical Ontologies, in which I have participated, are reported. Furthermore, the thesis presents a framework for consistently connecting the Gene Ontology (the most prominent of ontologies covered by OBO) with the Taxonomy of Species, and discusses the benefits of its prospective adoption by the OBO community. ii Acknowledgments This dissertation is submitted to the Norwegian University of Science and Technology (NTNU) in partial fulfillment of the requirements for the degree doktor ingeniør (PhD). It reflects and partially reports my work done at the Department of Computer and Information Science (IDI) in the course of a graduate study under the guidance of professors Jan Komorowski, Astrid Lægreid, Agnar Aamodt, and Barry Smith. I would not have achieved much without support from my supervisors, col- laborators, and colleagues. My work at the Norwegian University of Science and Technology (NTNU) in Trondheim was initially part of a research ini- tiative in functional genomics, conducted under the guidance of prof. Jan Komorowski,1 prof. Astrid Lægreid,2 and prof. Arne Sandvik.3 It is these three people, and especially Jan and Astrid, whom I owe thanks for intro- ducing me to the field and for inviting me to be a member of their research team. Special thanks go to prof. Agnar Aamodt,4 who agreed to become my supervisor after prof. Komorowski had left for Sweden. I am deeply grateful for prof. Aamodt’s having introduced me to Artificial Intelligence, Machine Learning, and Case-Based Reasoning; for his faith in my ability to succeed; and for his continuous support in my efforts to find the right environment and an appropriate research target. Last, but not least among my tutors, 1Prof. Komorowski is currently the Scientific Director of the Linnaeus Center for Bioinformatics at the Uppsala University, Sweden (http://www.lcb.uu.se/). 2Prof. Lægreid is currently a Prorector at NTNU. 3Prof. Sandvik is currently a Project Leader at the NTNU Microarray Core Facility. 4Prof. Aamodt is currently the Leader of the Division of Intelligent Systems at IDI, NTNU. iii iv prof. Barry Smith5 deserves particular appreciation for introducing me to the Open Biomedical Ontologies community, for involving discussions, and for inviting me to visit him and his research team in Saarbrücken. I would like to thank my colleagues at the Institute for their help, discus- sions, and company. I thank Jörg for helping me in recovering from in- numerable annoyances of LATEX and TEX, and for discussions on these and many other issues. I would also like to thank those at IDI with whom I had the chance to collaborate in teaching — this was a great experience. Ku- dos to all members of the administration staff for their support in solving mundane problems. I am also grateful to colleagues from the Department of Cancer Research and Molecular Medicine (IKM) and other institutes at the Faculty of Medicine (DMF) at NTNU who helped me or allowed me to participate in their projects. I owe thanks to those members of the Ontolog Forum6 who, with amazing patience and understanding, responded to my questions, complaints, and claims. Last not least, the warmest thank you to my closest family for all the support and encouragement they have been giving me throughout the whole period of my study and writing. 5Prof. Smith is an internationally renowned philosopher-ontologist; currently, he is, among oth- ers, the Director of the Institute for Formal Ontology and Medical Information Science (IFOMIS) in Saarbrücken, Germany, and a member of the Scientific Advisory Board of the Gene Ontology Consortium. 6http://ontolog.cim3.net/. Contents 1 Outline 1 1.1 ResearchOverview ........................ 2 1.1.1 Phase I: Analysis and Mining of Microarray Data . 2 1.1.2 Phase II: Knowledge-Guided Microarray Data Analysis 6 1.1.3 Phase III: Biomedical Ontology Engineering . 11 1.1.4 Research Summary . 15 1.2 ThesisOverview .......................... 21 2 Background 25 2.1 Introduction ............................ 26 2.2 Bioinformatics and Computational Biology . 27 2.3 Data, Information, Knowledge . 29 2.4 BiomedicalData .......................... 31 2.5 DataIntegration .......................... 39 2.6 Standardization .......................... 45 2.7 BiomedicalOntologies . 52 3 Standardization in Biomedical Ontology 63 3.1 Introduction ............................ 64 3.2 [N]ontologicalEngineering. 65 3.2.1 KnowledgeandModels. 67 3.2.2 ConceptsandClasses . 71 3.2.3 Classes and Individuals . 73 3.2.4 FurtherNotes ....................... 76 3.3 A Philosophical Framework for Bio-Ontologies . 77 v vi CONTENTS 3.3.1 Reality and Representation . 79 3.3.2 Three Levels of Reality . 80 3.3.3 (Against) The Concept Orientation . 82 3.3.4 BasicFormalOntology . 86 3.3.5 Discussion ......................... 95 4 Subsetting the GO with Slims 97 4.1 Introduction ............................ 98 4.2 The Generality and Specificity of GO Terms . 100 4.3 TheGOSlims ........................... 101 4.3.1 GO Slims Have Imprecisely Defined Scope . 104 4.3.2 ‘Species-Specificity’ Has Imprecise Meaning . 106 4.3.3 Relations Between Taxa Are Neglected . 107 4.3.4 SlimsAreBuiltManually . 109 4.3.5 Slims Are Updated Manually . 109 4.4 Discussion ............................. 110 5 ConnectingtheGOandtheTS 111 5.1 Introduction ............................ 112 5.2 Relations Between the GO and the TS . 113 5.2.1 Validity........................... 114 5.2.2 Specificity ......................... 115 5.2.3 Relevance ......................... 115 5.2.4 Additional Notes . 116 5.3 InferencePatterns—RulesofPropagation . 117 5.3.1 Logical Properties of the Rules of Propagation . 119 5.3.2 ConsequencesofPropagation . 119 5.4 Dynamic Partitioning of the GO . 121 5.5 Discussion ............................. 123 5.5.1 Implementation of the Framework . 125 5.5.2 Manually Created and Inferred Assertions . 125 5.5.3 Epistemologicalissues . 126 5.5.4 Logical Implications . 127 5.5.5 Propagation along ‘Part of’ Relations . 128 5.5.6 A Note on the Terminology . 129 CONTENTS vii 6 Concluding Remarks 131 6.1 GoalsandQuestionsRevisited . 131 A Formalization of the Framework 139 A.1 Introduction ............................ 140 A.2 LOF — A Formalism for the GO-TS Framework . 141 A.2.1 The Vocabulary of LOF .................. 142 A.2.2 The Syntax of LOF ..................... 142 A.2.3 The Semantics of LOF ................... 143 A.3 Monotonic Inference in LOF ................... 148 A.3.1 Inference from ΦAS-Sentences . 148 A.3.2 Inference from ΦSS-Sentences . 149 A.3.3 Inference from ΦRSS-Sentences . 150 A.3.4 Inference from ΦOS-Sentences. 152 A.3.5 ΦSS-Sentences versus ΦRSS, ΦAS, and ΦOS-Sentences . 152 A.4 Non-Monotonic Inference in LOF ................. 153 A.5 Discussion ............................. 154 A.5.1 Existential Claims . 154 A.5.2 The Choice of species ................... 156 A.5.3 Translation to Other Formalisms . 157 B Critical Assessment of Taxonomic Databases 159 B.1 Introduction ............................ 160 B.1.1 The Need for Taxonomic Annotation . 160 B.2 TheProblemofSpecies . 162 B.2.1 OntoClean: Species are Metaclasses . 164 B.3 Taxonomic Classifications and Nomenclatures . 167 B.4 ProblemswiththeTaxonomy. 168 B.4.1 Taxonomic Databases . 168 B.4.2 TaxonomicRanks . 169 B.4.3 RankOrders ........................ 171 B.4.4 RankNames ........................ 175 B.4.5 Taxa and Their Ranks . 176 B.4.6 Taxa and Their Names . 178 B.5 Discussion ............................. 182 viii CONTENTS Bibliography 184 List of Figures 1.1 A biological association network from
Recommended publications
  • Analyses of Allele-Specific Gene Expression in Highly Divergent
    ARTICLES Analyses of allele-specific gene expression in highly divergent mouse crosses identifies pervasive allelic imbalance James J Crowley1,10, Vasyl Zhabotynsky1,10, Wei Sun1,2,10, Shunping Huang3, Isa Kemal Pakatci3, Yunjung Kim1, Jeremy R Wang3, Andrew P Morgan1,4,5, John D Calaway1,4,5, David L Aylor1,9, Zaining Yun1, Timothy A Bell1,4,5, Ryan J Buus1,4,5, Mark E Calaway1,4,5, John P Didion1,4,5, Terry J Gooch1,4,5, Stephanie D Hansen1,4,5, Nashiya N Robinson1,4,5, Ginger D Shaw1,4,5, Jason S Spence1, Corey R Quackenbush1, Cordelia J Barrick1, Randal J Nonneman1, Kyungsu Kim2, James Xenakis2, Yuying Xie1, William Valdar1,4, Alan B Lenarcic1, Wei Wang3,9, Catherine E Welsh3, Chen-Ping Fu3, Zhaojun Zhang3, James Holt3, Zhishan Guo3, David W Threadgill6, Lisa M Tarantino7, Darla R Miller1,4,5, Fei Zou2,11, Leonard McMillan3,11, Patrick F Sullivan1,5,7,8,11 & Fernando Pardo-Manuel de Villena1,4,5,11 Complex human traits are influenced by variation in regulatory DNA through mechanisms that are not fully understood. Because regulatory elements are conserved between humans and mice, a thorough annotation of cis regulatory variants in mice could aid in further characterizing these mechanisms. Here we provide a detailed portrait of mouse gene expression across multiple tissues in a three-way diallel. Greater than 80% of mouse genes have cis regulatory variation. Effects from these variants influence complex traits and usually extend to the human ortholog. Further, we estimate that at least one in every thousand SNPs creates a cis regulatory effect.
    [Show full text]
  • Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2016-10-14 Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens Victoria E. Pedanou University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biology Commons, and the Cancer Biology Commons Repository Citation Pedanou VE. (2016). Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens. GSBS Dissertations and Theses. https://doi.org/10.13028/M27G6D. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/889 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. i TITLE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY OCTOBER 14TH, 2016 CANCER BIOLOGY ii SIGNATURE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU This work was undertaken in the Graduate School of Biomedical Sciences Cancer Biology The signature of the Thesis Advisor signifies validation of Dissertation content ___________________________ Michael R. Green, Thesis Advisor The signatures of the Dissertation Defense Committee signify completion and approval as to style and content of the Dissertation __________________________________ Eric H.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • Revostmm Vol 10-4-2018 Ingles Maquetaciûn 1
    108 ORIGINALS / Rev Osteoporos Metab Miner. 2018;10(4):108-18 Roca-Ayats N1, Falcó-Mascaró M1, García-Giralt N2, Cozar M1, Abril JF3, Quesada-Gómez JM4, Prieto-Alhambra D5,6, Nogués X2, Mellibovsky L2, Díez-Pérez A2, Grinberg D1, Balcells S1 1 Departamento de Genética, Microbiología y Estadística - Facultad de Biología - Universidad de Barcelona - Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) - Instituto de Salud Carlos III (ISCIII) - Instituto de Biomedicina de la Universidad de Barcelona (IBUB) - Instituto de Investigación Sant Joan de Déu (IRSJD) - Barcelona (España) 2 Unidad de Investigación en Fisiopatología Ósea y Articular (URFOA); Instituto Hospital del Mar de Investigaciones Médicas (IMIM) - Parque de Salud Mar - Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES); Instituto de Salud Carlos III (ISCIII) - Barcelona (España) 3 Departamento de Genética, Microbiología y Estadística; Facultad de Biología; Universidad de Barcelona - Instituto de Biomedicina de la Universidad de Barcelona (IBUB) - Barcelona (España) 4 Unidad de Metabolismo Mineral; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC); Hospital Universitario Reina Sofía - Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES); Instituto de Salud Carlos III (ISCIII) - Córdoba (España) 5 Grupo de Investigación en Enfermedades Prevalentes del Aparato Locomotor (GREMPAL) - Instituto de Investigación en Atención Primaria (IDIAP) Jordi Gol - Centro de Investigación
    [Show full text]
  • Delineation of Key Regulatory Elements Identifies Points Of
    DELINEATION OF KEY REGULATORY ELEMENTS IDENTIFIES POINTS OF VULNERABILITY IN THE MITOGEN-ACTIVATED SIGNALING NETWORK SUPPLEMENTARY MATERIALS List of contents Supplementary Figures with legends 1. Figure S1: Distribution of primary siRNA screen data, and standardization of assay procedure. 2. Figure S2: Scatter plot of screen data. 3. Figure S3: Functional relevance of the identified targets and Calculation of residence time from PDT and cell cycle distribution. 4. Figure S4: FACS profiles for ABL1 and AKT1. Table for data in Figure 5B. 5. Figure S5: Venn diagram showing the results of the comparative analysis of other screen results 6. Figure S6: Dose response profiles for the AKT1 + ABL1 inhibitor combination for CH1, list of the 14 cell lines and their description, effect of ABL1+AKT1 inhibitor combination on increase in apoptotic cells and G1 arrest in 14 cell lines, effects of CHEK1 inhibitor on combination C1,C2 on 4 cell lines. Supplementary Tables 1. Table S1: siRNA screen results for targeted kinases and phosphatases. 2. Table S2: Gene expression status of the validated hits. 3. Table S3: Role played by identified RNAi hits in regulation of cell cycle, the effect on PDTs along with phase-specific RTs. 4. Table S4: List of molecules classified as cell cycle targets. 5. Table S5: High confidence network used for graph theory analysis. 6. Table S6: Occurrences of nodes in shortest path networks. 7. Table S7: Network file used as SNAVI background. 8. Table S8: Classification of nodes present in modules according to specificity. Legends for tables Supplementary Experimental Procedures References Figure S1 A 450 400 G1 S 350 G2 300 250 200 150 100 50 Distribution of molecules Distribution 0 -6-4-20246 Z-score 350 200 400 G1 S 300 G2 150 300 250 200 100 200 150 100 50 100 Distribution of molecules 50 0 0 0 -4 -2 0 2 4 -4-20246 -4-20246 Z-score B PLK1 GAPDH PLCg BTK PLCg CDC2A PLCg CHEK1 PLCg MET Distribution profiles of complete primary screen and western blots showing knockdown efficiency.
    [Show full text]
  • Table 3: Average Gene Expression Profiles by Chromosome
    Supplemental Data Table 1: Experimental Setup Correlation Array Reverse Fluor Array Extraction Coefficient Print Batch (Y/N) mean (range) DLD1-I.1 I A N DLD1-I.2 I B N 0.86 DLD1-I.3 I C N (0.79-0.90) DLD1-I.4 I C Y DLD1 DLD1-II.1 II D N DLD1-II.2 II E N 0.86 DLD1-II.3 II F N (0.74-0.94) DLD1-II.4 II F Y DLD1+3-II.1 II A N DLD1+3-II.2 II A N 0.85 DLD1 + 3 DLD1+3-II.3 II B N (0.64-0.95) DLD1+3-II.4 II B Y DLD1+7-I.1 I A N DLD1+7-I.2 I A N 0.79 DLD1 + 7 DLD1+7-I.3 I B N (0.68-0.90) DLD1+7-I.4 I B Y DLD1+13-I.1 I A N DLD1+13-I.2 I A N 0.88 DLD1 + 13 DLD1+13-I.3 I B N (0.84-0.91) DLD1+13-I.4 I B Y hTERT-HME-I.1 I A N hTERT-HME-I.2 I B N 0.85 hTERT-HME hTERT-HME-I.3 I C N (0.80-0.92) hTERT-HME-I.4 I C Y hTERT-HME+3-I.1 I A N hTERT-HME+3-I.2 I B N 0.84 hTERT-HME + 3 hTERT-HME+3-I.3 I C N (0.74-0.90) hTERT-HME+3-I.4 I C Y Supplemental Data Table 2: Average gene expression profiles by chromosome arm DLD1 hTERT-HME Ratio.7 Ratio.1 Ratio.3 Ratio.3 Chrom.
    [Show full text]
  • Concordance of Copy Number Loss and Down-Regulation of Tumor Suppressor Genes: a Pan-Cancer Study Min Zhao1 and Zhongming Zhao2,3,4,5*
    The Author(s) BMC Genomics 2016, 17(Suppl 7):532 DOI 10.1186/s12864-016-2904-y RESEARCH Open Access Concordance of copy number loss and down-regulation of tumor suppressor genes: a pan-cancer study Min Zhao1 and Zhongming Zhao2,3,4,5* From The International Conference on Intelligent Biology and Medicine (ICIBM) 2015 Indianapolis, IN, USA. 13-15 November 2015 Abstract Background: Tumor suppressor genes (TSGs) encode the guardian molecules to control cell growth. The genomic alteration of TSGs may cause tumorigenesis and promote cancer progression. So far, investigators have mainly studied the functional effects of somatic single nucleotide variants in TSGs. Copy number variation (CNV) is another important form of genetic variation, and is often involved in cancer biology and drug treatment, but studies of CNV in TSGs are less represented in literature. In addition, there is a lack of a combinatory analysis of gene expression and CNV in this important gene set. Such a study may provide more insights into the relationship between gene dosage and tumorigenesis. To meet this demand, we performed a systematic analysis of CNVs and gene expression in TSGs to provide a systematic view of CNV and gene expression change in TSGs in pan-cancer. Results: We identified 1170 TSGs with copy number gain or loss in 5846 tumor samples. Among them, 207 TSGs tended to have copy number loss (CNL), from which fifteen CNL hotspot regions were identified. The functional enrichment analysis revealed that the 207 TSGs were enriched in cancer-related pathways such as P53 signaling pathway and the P53 interactome.
    [Show full text]
  • Redalyc.Loss of Heterozygosity in the Short Arm of Human Chromosome 3
    Colombia Médica ISSN: 0120-8322 [email protected] Universidad del Valle Colombia BARRERA, LINA MARCELA; ÁLVAREZ, LIZETH MARELLY; ROLDÁN, MIGUEL IGNACIO; ORTEGA, HÉCTOR; TRIANA, OMAR; MARTÍNEZ, ALONSO Loss of heterozygosity in the short arm of human chromosome 3 in sporadic lung cancer Colombia Médica, vol. 41, núm. 4, octubre-diciembre, 2010, pp. 358-366 Universidad del Valle Cali, Colombia Disponible en: http://www.redalyc.org/articulo.oa?id=28315594010 Cómo citar el artículo Número completo Sistema de Información Científica Más información del artículo Red de Revistas Científicas de América Latina, el Caribe, España y Portugal Página de la revista en redalyc.org Proyecto académico sin fines de lucro, desarrollado bajo la iniciativa de acceso abierto Colombia Médica Vol. 41 Nº 4, 2010 (Octubre-Diciembre) Loss of heterozygosity in the short arm of human chromosome 3 in sporadic lung cancer* LINA MARCELA BARRERA, BIOL1**, LIZETH MARELLY ÁLVAREZ, BIOL.1**, MIGUEL IGNACIO ROLDÁN, MD2, HÉCTOR ORTEGA, MD3, OMAR TRIANA, PHD4, ALONSO MARTÍNEZ, PHD5 SUMMARY Introduction: Loss of Heterozygocity (LOH) in the short arm of human chromosome 3 (3p) is a frequent event in different types of sporadic tumors, including lung cancer (LC). Aim: To determine 3p LOH in LC samples using 17 microsatellite markers. Methodology: In a pilot study on volunteers, thirteen LC biopsies (tumor tissue) and 4 ml of blood (normal tissue) from the same patient were collected. DNA extraction and Polymerase Chain Reaction (PCR) were performed with 17 microsatellite markers to analyze LOH. Amplified fragments were run on 6% denaturalizing polyacrilamide gels and were visualized by using silver stain.
    [Show full text]
  • Mechanisms of FUS1/TUSC2 Deficiency in Mesothelioma and Its
    Molecular Cancer BioMed Central Research Open Access Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects Alla V Ivanova*1, Sergey V Ivanov2, Ljudmila Prudkin3, Daisuke Nonaka2, Zhandong Liu4, Anne Tsao3, Ignacio Wistuba3, Jack Roth5 and Harvey I Pass2 Address: 1Hematology/Oncology Division, Vanderbilt Medical Center, Nashville, TN, USA, 2Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY, USA, 3Department of Thoracic/Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX, USA, 4Genomics and Computational Biology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA and 5Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA Email: Alla V Ivanova* - [email protected]; Sergey V Ivanov - [email protected]; Ljudmila Prudkin - [email protected]; Daisuke Nonaka - [email protected]; Zhandong Liu - [email protected]; Anne Tsao - [email protected]; Ignacio Wistuba - [email protected]; Jack Roth - [email protected]; Harvey I Pass - [email protected] * Corresponding author Published: 24 October 2009 Received: 6 August 2009 Accepted: 24 October 2009 Molecular Cancer 2009, 8:91 doi:10.1186/1476-4598-8-91 This article is available from: http://www.molecular-cancer.com/content/8/1/91 © 2009 Ivanova et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Anti-ASAP2 (Aa 5-194) Polyclonal Antibody (DPABH-00543) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-ASAP2 (aa 5-194) polyclonal antibody (DPABH-00543) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Activates the small GTPases ARF1, ARF5 and ARF6. Regulates the formation of post-Golgi vesicles and modulates constitutive secretion. Modulates phagocytosis mediated by Fc gamma receptor and ARF6. Modulates PXN recruitment to focal contacts and cell migration. Immunogen Synthetic peptide, corresponding to a region within N terminal amino acids 5-194 of Human PAG3 (UniProt ID: O43150-2). Isotype IgG Source/Host Rabbit Species Reactivity Mouse, Human Purification Immunogen affinity purified Conjugate Unconjugated Applications WB Format Liquid Size 100 μl Buffer pH: 7.00; Constituents: 0.75% Glycine, 1.21% Tris, 20% Glycerol Preservative None Storage Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. GENE INFORMATION Gene Name ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 [ Homo sapiens ] Official Symbol ASAP2 Synonyms ASAP2; ArfGAP with SH3 domain, ankyrin repeat and PH domain 2; PAP; PAG3; AMAP2; DDEF2; SHAG1; CENTB3; Pap-alpha; arf-GAP with SH3 domain, ANK repeat and PH domain- 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved containing protein 2; centaurin, beta 3; PYK2 C terminus-associated protein; pyk2 C-terminus- associated protein; development and differentiation enhancing factor 2; development and differentiation-enhancing factor 2; paxillin-associated protein with ARF GAP activity 3; Entrez Gene ID 8853 Protein Refseq NP_001128663.1 UniProt ID O43150 Pathway Arf6 trafficking events; Endocytosis; Fc gamma R-mediated phagocytosis; Function ARF GTPase activator activity; enzyme activator activity; protein binding; zinc ion binding 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.
    [Show full text]